Top Stocks to Watch: June 25, 2025 Edition

June 25, 2025

DENVER, Colo., Jun 25, 2025 (247marketnews.com)- Plus Therapeutics (NASDAQ:PSTV) just announced a significant regulatory win with FDA clearance of its IND application for REYOBIQ (Rhenium Re186 Obisbemeda), targeting rare pediatric brain cancers. The newly approved ReSPECT-PBC trial—funded by a $3M Department of Defense grant—focuses on high-grade gliomas and ependymomas, cancers with few effective treatments and poor survival rates.

The trial’s novel use of Convection-Enhanced Delivery (CED) to bypass the blood-brain barrier positions Plus at the forefront of targeted radiotherapy innovation. If successful, REYOBIQ could transform treatment protocols for these aggressive tumors, making PSTV a compelling long-term biotech play.

Sonim Technologies (NASDAQ:SONM) is trying to redefine its trajectory, by signing a Letter of Intent for a reverse takeover with a private U.S. company specializing in Nvidia-powered AI factories and HPC-as-a-Service. This transition from rugged mobile devices to AI infrastructure represents a dramatic pivot, underscored by a projected $300M valuation for the private firm and a $17.5M equity stake retained by Sonim shareholders.

Venu’s (NYSE:VENU) CEO, J.W. Roth, unveiled, in a letter to shareholders, an ambitious update outlining multiple growth catalysts, including partnerships with Aramark Sports + Entertainment and Billboard, and groundbreakings for high-profile venues in Texas, Oklahoma, and Colorado.

These venues, like the 20,000-seat Sunset Amphitheater in McKinney, TX, are being developed under a real estate-first model, designed to generate diversified revenues through events, fractional suite ownership, and premium hospitality.

Glucotrack (NASDAQ:GCTK) reported strong clinical data from its first-in-human trial of a long-term, blood-based continuous glucose monitor (CBGM) at the American Diabetes Association’s 85th Scientific Sessions. With a Mean Absolute Relative Difference (MARD) of 7.7%, the device showed excellent accuracy and safety, with no serious adverse events.

Unlike current interstitial-based monitors, Glucotrack’s sensor uses actual blood glucose, significantly reducing lag time and improving real-time monitoring—a key need for insulin-dependent diabetics.

QuantumScape (NYSE:QS) continues to ride the wave of solid-state battery excitement. Analysts and investors are closely watching for the next update on production timelines, particularly as QS edges closer to delivering prototype cells to automotive partners.

Surf Air Mobility (NYSE:SRFM), focused on regional air mobility and electrified aviation, is navigating regulatory milestones and expanding its commercial flight footprint. While specific new developments were not released this week, the company is expected to announce progress on FAA certification for hybrid-electric aircraft and fleet scaling efforts in underserved U.S. regions.

Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure information.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (PSTV, SONM, VENU, GCTK, QS, SRFM)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.